Journal Article

Recombinant human erythropoietin corrects anaemia during the first weeks after renal transplantation: a randomized prospective study

A. Van Loo, R. Vanholder, P. Bernaert, J. De Roose and N. Lameire

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 11, issue 9, pages 1815-1821
Published in print September 1996 | ISSN: 0931-0509
e-ISSN: 1460-2385 | DOI: http://dx.doi.org/10.1093/oxfordjournals.ndt.a027674
Recombinant human erythropoietin corrects anaemia during the first weeks after renal transplantation: a randomized prospective study

Show Summary Details

Preview

Background.

Studies on the effect of recombinant human erythropoietin (rHuEpo) on haematopoiesis in patients with kidney transplants, have been limited to progressive chronic graft failure, late after transplantation. In the present prospective randomized study, the efficacy of rHuEpo in the correction of anaemia during the first weeks after renal transplantation (RTP) was evaluated.

Methods.

Patients were allocated to either an Epo-(n=14) or a non-Epo-treated group (n=15). Epo (150 U/kg.week s.c.) was started at a haematocrit (Hct) <30% and was increased at weekly intervals by 30 U/kg.week, as long as Hct remained <25%.

Results.

In the Epo group, Hct increased from a nadir of 22±4% 2 weeks after RTP to 30±4% at week 4 and to 36±4% at week 6 (P<0.001 and P<0.0001 respectively vs week 2). Corresponding values in the non-Epo group were 25±6%, 28±6% (P=NS) and 32±6% (P<0.05 vs week 2) (overall evolution Epo vs non-Epo: P=0.038 by variance analysis). The differences in Hct between the Epo and non Epo group were even more marked in patients without major complications (variance analysis P=0.009). The Epotreated patients required fewer post-surgical blood transfusions (0.005 vs 0.014/days follow-up, P<0.05), in spite of greater post-surgical blood losses, especially at day 1 (P<0.05) and the presence of more major complications (7 vs 4) and a higher number of ganciclo vir-treated patients (4 vs 0; P<0.05). The maximum Epo dose after RTP was >2× higher than the one required before RTP (197.1±45.1 vs 85.0±76.0 U/kg.week; P<0.05).

Conclusions.

It is concluded that rHuEpo during the first weeks after RTP is of benefit in the correction of the Hct in the early post-surgical period, in spite of relative Epo resistance.

Keywords: anaemia; erythropoietin; haematocrit; kidney transplantation; renal transplantation

Journal Article.  0 words. 

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.